For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor ...

Substance use disorders (SUDs) are a major public health concern, with opioid use disorder (OUD) and alcohol use disorder ...

and colleagues examined the impact of GLP-1 RA use on EO-CRC risk. The analysis included data from roughly 1.8 million patients (aged younger than 50 years) with a diagnosis of type 2 diabetes ...

Despite crowding in the next-gen weight loss space, Metsera has raised over $500 million since its April launch, indicating a ...

Metsera is riding the wave of continued enthusiasm for GLP-1 drugs and its own early-stage data to bring in ... There is also ...

After inverse probability of treatment weighting, the researchers identified 1,924 recurrent nephrolithiasis events among ...

"I'm using [Ozempic] off-label for a whole host of conditions — and have been for years," Dr. Caroline Messer, an ...

While Novo Nordisk says CagriSema will help users lose up to 25% of weight, duration will be clear when final results of its ...

As the FDA issues a new warning about aspiration across all GLP-1 weight loss drugs, doctor groups are giving new ...

Stroke survivors who took GLP-1 or SGLT2 medications had a 74% lower risk of death, according to a preliminary study being presented at the American Heart Association's annual Scientific Sessions, set ...

Metsera is looking to both improve on that class of drugs, known as GLP-1 inhibitors, as well as offer other options. The ...